The market for the cancer screening is found to be valued at $XX billion in 2015. At the end of 2015, the market is estimated to be $XX billion and is estimated to reach around $XX billion by 2021, growing at a CAGR of XX% from 2016 to 2021. This scenario is expected to further revolutionize the industry towards massive growth in the next 5 to 10 years because of the technological advancements and developments in the medicines in cancer diagnosis and effective health care.
Though the cost of diagnosis is one of the main constraints, government support and indigenous technologies from countries such China, India, and Japan is helping the market penetration. A simple blood test could be on the way to replacing the biopsy as the gold standard for detecting cancer, saving lives and money, according to researchers in the U.K. In their study, carried out on known or suspected primary or secondary lung cancer who were about to undergo surgery, the blood test was accurate in predicting the presence of cancer cells in nearly 70% of cases.
The above table explains the classification of cancer testing techniques which healthcare systems follow or usually doctors follow depending upon the type of cancer or techniques or by operation or selection of particular technique depending upon the stage of cancer. The stages of cancer refer to the severity of tumor or the time period from which it’s been affecting the human body.
The major cause for the cancer is smoking and tobacco consumption and there are over 100 varieties of cancer depending upon various factors like the body part to which it is affected such as lung cancer, blood cancer, cervical cancer, breast cancer, abdominal cancer and screening techniques can be classified depending upon the type it is going to be diagnosed or may be depending upon the procedure which the particular method they follow such as imaging techniques (Computed tomography (CT) scan, Magnetic resonance imaging (MRI) scan, X-rays and other radiographic tests, Mammography, Ultrasound), endoscopy (arthroscopy, nronchoscopy, nystoscopy, laparoscopy, neuroendoscopy), bio marker tests, and also based on the technologies which the process follow and also on the treatment which they follow such as surgery, radiation, chemotherapy, immunotherapy, hormone therapy, gene therapy.
The high cancer rate is observed in countries such as Denmark, Australia, Belgium, Norway, Ireland, and North Korea whereas the low cancer rate is found in Niger, Columbia, Nepal, Namibia, and Bhutan etc. The most widely affected cancer areas where these cancer-testing techniques are followed can be segmented based on the geography such as Europe, America, APAC, and RoW can be segmented whereas the major portion is occupied by the Europe followed by Americas followed by APAC countries.
Please Note: The report is to be delivered in 1-2 working days after an order is placed.
2. Executive Summary
3. Cacer Testing Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.2.1. Product Benchmarking
3.2.2. End User Profiling
3.2.3. Top 5 Financials Analysis
4. Cancer Testing Market Forces
4.1. Market Drivers
4.2. Market Constraints & Challenges
4.3. Attractiveness Of Cancer Testing Industry
4.3.1. Power Of Suppliers
4.3.2. Threats From New Entrants
4.3.3. Power Of Buyer
4.3.4. Threat From Substitute Product
4.3.5. Degree Of Competition
5. Cancer Testing Market Strategic Analysis
5.1. Cancer Testing - Value Chain Analysis
5.2. Pricing Analysis
5.3. Opportunity Analysis
5.4. Product Life Cycle
5.5. Suppliers And Distributors
6. Cancer Testing Market-By Type
6.2. Lung Cancer
6.3. Blood Cancer
6.4. Bone Cancer
6.5. Abdominal Cancer
6.6. Eye Cancer
6.7. Mouth Cancer
6.8. Breast (Women) Cancer
7. Cancer Testing Market-By Technique
7.2. Imaging Techniques
7.3. Bio Marker Tests
7.5. Radiation Techniques
8. Cancer Testing Market-By Treatment
8.4. Hormone Therapy
8.5. Chemo Therapy
8.6. Gene Therapy
9. Cancer Testing Market-By Stage
9.1. Tnm Stages
9.2. Stages 0,1,2,3,4
9.3. Prognostic Factors
9.4. Other Staging Systems
10. Cancer Testing Market- By Gender
11. Cancer Testing Market-By Geography
11.1.5. Rest Of America
11.2.6. Rest Of Europe
11.3. Asia Pacific
11.3.2. South Korea
11.3.3. Australia & New Zealand
11.3.6. Rest Of Apac
11.4. Rest Of The World (Row)
11.4.1. Middle East Africa
12. Cancer Testing Market -Entropy
12.1. New Product Developments
12.2. Product Launchers, Jvs, Mergers And Acquisitions
13. Company Profiles
13.1. Dias Orin S.P.A
13.2. Immunodiagnostic Systems Holdings Plc
13.3. Epigenomics Ag
13.4. Techlab, Inc.
13.5. Genextropy, Inc.
13.7. Genclis Sa
13.8. Target Discovery
13.9. Positive Bioscience
13.10. Celdara Medical, Llc
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"